Mumbai, Feb. 27 -- A quadrivalent vaccine, by covering strains of both influenza A and influenza B, provides broader protection and significantly reduces the risk of vaccine mismatch. The vaccine has been cleared by the Central Drug Laboratory (CDL), the company added.

VaxiFlu-4 is being marketed by Zydus Vaxxicare, a division of the group focusing on preventives. The Quadrivalent Inactivated Influenza vaccine has been developed at the Vaccine Technology Centre (VTC) in Ahmedabad, which has proven capabilities in researching, developing, and manufacturing safe and efficacious vaccines.

Influenza is a contagious respiratory illness caused by influenza viruses, which spread from person to person mainly through airborne respiratory droplet...